Previous attempts to pharmacologically inhibit SRC-3 show effectiveness <i>in vivo</i> and <i>in vitro</i> in other B cell lymphomas, and previous studies have shown that SRC-3 is highly expressed in the lymph nodes of B cell non-Hodgkin's lymphoma patients. Here, NCOA3 is linked to B-cell non-Hodgkin lymphoma.